Clinical trial · Interventional
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
A Randomized, Open-label, Multi-center Phase II Study to Compare AUY922 With Docetaxel or Irinotecan in Adult Patients With Advanced Gastric Cancer, Who Have Progressed After One Line of Chemotherapy
NCT01084330CI-TRIAL-00048789completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastro-esophageal Junction Cancer | Gastric Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AUY922 | Drug | Luminespib | ALIAS |
| Docetaxel | Drug | Docetaxel | ALIAS |
| Irinotecan | Drug | Irinotecan | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- AUY922
- interventionNames
- Drug: AUY922
- type
- ACTIVE_COMPARATOR
- label
- Docetaxel or Irinotecan
- interventionNames
- Drug: Docetaxel
- Drug: Irinotecan
Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- 21 day cycle: treatment until death, lost to follow up or withdrawal
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Radiologically confirmed advanced gastric cancer * One previous line of chemotherapy * Progressive disease * One measurable lesion * Blood tests within protocol ranges * (WHO) Performance Status ≤ 1 * Able to sign informed consent Exclusion Criteria: * No symptomatic brain metastases * No coumarin type anticoagulants * No liver or kidney disease * No impaired heart function * No pregnant or lactating women Other protocol-defined inclusion/exclusion criteria may apply
References
Publications (0)
Data not yet available
No reference posted for this study.